

Curriculum Vitae

Dr Patrick Allen FRCP (UK) BSc Hons Dip Ed

E mail: drpallengastro@gmail.com

GMC No **6050574**

Academic Qualifications

- July 2020 Nominated to the Committee of the Irish Society of Gastroenterology
- Aug 2018 Nominated Chair of the NI Research Network
- Aug 2017 Awarded Fellowship Royal College of Physician Edinburgh
- July 2017 Chair of the 4 Nations Committee BSG
- Aug 2012 Diploma in Education for the Healthcare Sciences
- Aug 2010 Honorary Clinical Lecturer QUB (Belfast)
- Aug 2010 Accredited Bowel cancer screener
- July 2010 Faculty Trainer on "Train the Trainers Colonoscopy Course"
- June 2002 MB BCh BAO with distinction in Final MB Medicine and Surgery. QUB Belfast.
- June 1999 Bachelor of Science. 1st class Honours degree in Therapeutics and Pharmacology. QUB Belfast.

Medicolegal Experience

I have been in medico-legal practice for 15 years, in the fields of personal injury and medical negligence.

I have an approximately even split between Claimant and Defendant instructions.

I am a member of the UK Register of Expert Witnesses and the National Expert Witness Agency.

I am a member of the Ulster and Irish Medicolegal Societies.

I have supplied reports for the UK courts and Republic of Ireland.

Clinical Interests

- General Gastroenterology,
- Irritable bowel syndrome,
- Reflux, and Barretts Oesophagus,
- Coeliac disease,
- Dyspepsia,
- Indigestion,
- Upper GI cancer,
- Liver disease,
- Inflammatory Bowel diseases – including Crohn's disease, ulcerative colitis and microscopic colitis,
- Colonic cancer- detection and treatment,
- Early removal of colonic cancers and large colonic polyp, and

- Gastro-intestinal Bleeding

I am skilled in

- Gastroscopy (diagnostic and therapeutic)
- Colonoscopy (diagnostic and therapeutic)
- Bowel cancer screening,
- Endoscopic mucosal resection (upper and lower GI),
- Full thickness resection of early GI cancers,
- Gastro-intestinal bleeding management, and
- Capsule endoscopy.
- I insert PEG tubes and feeding tubes such as NG,NJ tubes and PEJ tubes.

I am also interested in Disability with regards Inflammatory Bowel Diseases and have been published research and collaborated with Australian, European and American institutions regarding this. I have given lectures at American, European, Australian, UK and Irish meetings.

Consultant Experience

I have been a Consultant in Gastroenterology for 15 years in NI. I was a clinical and research fellow in St Vincent's Hospital in Melbourne prior to taking up my consultant post. I gained experience as part of the tertiary referral nutrition and Inflammatory Bowel Diseases team.

I am involved with the Nutrition multi-disciplinary team in my Hospital trust and manage patients with complex nutritional requirements and inflammatory bowel disease patients. I am involved with TPN, NG feeding and insertion of PEG/ PEJ feeding tubes.

I am involved with Quality improvement in Gastroenterology at my hospital as part of the BSG initiative. I have been involved with providing a Complex Colonic Polyp Referral Network in NI and perform complex polypectomies including Endoscopic Mucosal Resection and Full Thickness Resection (for upper and lower GI cases) and have delivered national training courses for this.

Research

I have been involved with Clinical Research since 1999.

I am chair for the NI GI Research Network and liaise closely with the UK research network.

I lead a GI research team in Gastroenterology and have currently 14 clinical trials in progress in my institution where I am primary investigator.

I also have received research grants for Investigator led studies and am a speaker / participate in Specialist Advisory Boards for several different pharmaceutical companies.

I have published widely in peer reviewed journals.

Membership

I am a member of various academic societies including BSG, ISG, ECCO and AGA.

I was previously elected chair for the 4 Nations at the British Society of Gastroenterology, previously chaired the Four Nations Committee and was elected to the BSG IBD committee.

I am a committee member of the Irish Society of Gastroenterology.

I have previously been selected as an expert advisor for NICE.

Publications

1. Assessing disease control in IBD a real world cross sectional study in the UK (PODCAST-IBD). de Silva S, Steed H, Allen PB, Vegad C, Crooks J, Jaulim A, Hart A. *Curr Med Res Opin* 2024 Nov ; 40(11): 1847-54
2. The importance of high-quality 'big data' in the application of artificial intelligence in IBD. JJ, Brooks-Warburton J, Allen PB, Tham TC, Hoque S, Kennedy NA, Dhar A, Sebastian S. *Frontline Gastroenterol* 2022 Nov 17;14(3): 258-62
3. Microscopic colitis in NI an updated clinicopathological audit of compliance with European Guidelines. Moore M, Coleman HG, Allen PB, Loughrey MB. *Colorectal Dis* 2022 Dec 24(12); 1584-90.
4. Artificial Intelligence and IBD; practicalities and future prospects.
5. Brooks-Warburton J, Ashton J, Dhar A, Tham T, Allen PB, Hoque S, Lovat LB, Sebastian S. *Frontline Gastroenterol* 2021 dec 10;325-331.
6. Interventions for treating iron deficiency anaemic in IBD. IGordon M, Sinopoulou V, Iheozor-Ejiofor Z, Iqbal T, Allen P, Hoque S, Engineer J, Akobeng AK. *Cochrane Database Syst Rev* 2021 Jan.
7. Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective. Allen PB, Bonovas S, Danese S, Peyrin-Biroulet L. *Expert Opin Biol Ther.* 2020 Feb;20(2):151-161
8. Practice pattern variability in the management of acute severe colitis: a UK provider survey. Shaji Sebastian, ...Patrick B Allen, et al *Frontline Gastroenterology.* 2020; 11(4): 272–279.
9. Oesophageal Stents for Potentially Curable Oesophageal Cancer - A Bridge to Surgery? Tham JE, Tharian B, Allen PB, Spence G, Tham TC. *Ulster Med J.* 2019 Jan; 88(1):10-14. Epub 2019 Jan 22.
10. Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis. Sebastian S, ... Allen PB, et al. *Aliment Pharmacol Ther.* 2019 Sep;50(6):675-683
11. UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation. Yan Yiannakou, .. Patrick B. Allen, et al *Therap Adv Gastroenterology.* 2018;
12. Microscopic colitis: a population-based case series over a 9-year period in Northern Ireland. Moore M, Coleman HG, Allen PB, Loughrey MB. *Colorectal Dis.* 2018
13. Communication of alcohol and smoking lifestyle advice to the gastroenterological patient. Spence AD, Khasawneh M, Allen PB, Addley J. *Best Pract Res Clin Gastroenterology.* 2017 Oct;31(5):597-604
14. The role of smoking and alcohol behaviour in the management of inflammatory bowel disease. Khasawneh M, Spence AD, Addley J, Allen PB. *Best Pract Res Clin Gastroenterol.* 2017 Oct;31(5):553-559.
15. Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Allen PB, Olivera P, Emery P, Moulin D, Jouzeau JY, Netter P, Danese S, Feagan B, Sandborn WJ, Peyrin-Biroulet L. *Aliment Pharmacol Ther.* 2017 Apr;45(8):1058-1072
16. Preventing disability in inflammatory bowel disease. Allen PB, Gower-Rousseau C, Danese S, Peyrin-Biroulet L. *Therap Adv Gastroenterol.* 2017 Nov;10(11):865-876
17. Ulcerative colitis. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. *Lancet.* 2017 Apr 29;389(10080):1756-1770. doi: 10.1016/S0140-6736(16)32126-2. Epub 2016 Dec 1
18. What Proportion of Patients With Inflammatory Bowel Disease Want to Stop Infliximab Therapy? Conroy G, Clerc-Urmès I, Allen PB, Baumann C, Peyrin-Biroulet L. *Inflamm Bowel Dis.* 2016 Jul;22(7):E25-6
19. NOD2 gene variant is a risk factor for postoperative complications in patients with Crohn's disease: A genetic association study. Germain A, Guéant RM, Chamailard M, Allen PB, Bresler L, Guéant JL, Peyrin-Biroulet L. *Surgery.* 2016 Jul;160(1):74-80.
20. Immunomodulators for the treatment of Crohn's disease in adults: optimal use and prospects for future drug treatments. Allen PB, Peyrin-Biroulet L. *Expert Rev Clin Immunol.* 2016 Jul;12(7):741-9.
21. Self-medication with steroids in inflammatory bowel disease. Filipe V, Allen PB, Peyrin-Biroulet L. *Dig Liver Dis.* 2016 Jan;48(1):23-6. doi: 10.1016/j.dld.2015.10.010. Epub 2015 Oct 17.

22. Colorectal Cancer Risk Following Adenoma Removal: A Large Prospective Population-Based Cohort Study. Coleman HG, Loughrey MB, Murray LJ, Johnston BT, Gavin AT, Shrubsole MJ, Bhat SK, Allen PB, McConnell V, Cantwell MM. *Cancer Epidemiol Biomarkers Prev.* 2015 Sep;24(9):1373-80.
23. Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease? Gilroy L, Allen PB. *Clin Exp Gastroenterol.* 2014 May 22;7:163-72.
24. EBV-associated colonic B-cell lymphoma following treatment with infliximab for IBD: a new problem? Allen PB, Laing G, Connolly A, O'Neill C. *BMJ Case Rep.* 2013 Sep 30;2013.
25. Chromoendoscopy versus narrow band imaging for colonic surveillance in inflammatory bowel disease. Efthymiou M, Allen PB, Taylor AC, Desmond PV, Jayasakera C, De Cruz P, Kamm MA. *Inflamm Bowel Dis.* 2013 Sep;19(10):2132-8.
26. Moving towards disease modification in inflammatory bowel disease therapy. Allen PB, Peyrin-Biroulet L. *Curr Opin Gastroenterol.* 2013 Jul;29(4):397-404.
27. If it walks like Crohn's and talks like Crohn's, it must be... Hall PS, Allen PB, Diong KL, Varghese A. *BMJ Case Rep.* 2013 Jan 10;2013.
28. Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease. Allen PB, et al. *Aliment Pharmacol Ther.* 2013 Feb;37(4):438-44.
29. Postoperative recurrence of Crohn's disease: impact of endoscopic monitoring and treatment step-up. De Cruz P, ..., Allen PB, et al. *Colorectal Dis.* 2013 Feb;15(2):187-97.
30. Anti-adhesion molecules: is gut specificity the key for a good safety profile? Allen PB. *Curr Drug Deliv.* 2012 Jul;9(4):333-7.
31. Mucosal healing in Crohn's disease: a systematic review. De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. *Inflamm Bowel Dis.* 2013 Feb;19(2):429-44.
32. Postoperative recurrent luminal Crohn's disease: a systematic review. De Cruz P, Kamm MA, Prideaux L, Allen PB, Desmond PV. *Inflamm Bowel Dis.* 2012 Apr;18(4):758-77.
33. Gastroenterology training in Australia: a perspective from the coal face. De Cruz P, Leung C, Raftopoulos S, Allen PB, Burgell R, Rode A, Rosenbaum J, Bell SJ, Hebbard GS. *Intern Med J.* 2012 Oct;42(10):1125-30.
34. Value of fecal occult blood test as a screening test before capsule endoscopy. Efthymiou M, Allen PB, Jayasekera C, Taylor PV, Taylor AC. *Eur J Gastroenterol Hepatol.* 2011 Aug;23(8):690-4.
35. Update on Crohn's disease and ulcerative colitis. Billioud V, Allen PB, Peyrin-Biroulet L. *Expert Rev Gastroenterol Hepatol.* 2011 Jun;5(3):311-4.
36. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. Filippi J, Allen PB, Hébuterne X, Peyrin-Biroulet L. *Curr Drug Targets.* 2011 Sep;12(10):1440-7.
37. Nicorandil associated colonic ulceration: case series of an increasingly recognized complication. Lee BC, Allen PB, Caddy GR, Mainie I. *Dig Dis Sci.* 2011 Aug;56(8):2404-8.
38. Practical application of anti-TNF therapy for luminal Crohn's disease. Kamm MA, Ng SC, De Cruz P, Allen P, Hanauer SB. *IBD.* 2011 Nov;17(11):2366-91.
39. Noninvasive imaging of the small bowel in Crohn's disease: the final frontier. Allen PB, De Cruz P, Lee WK, Taylor S, Desmond PV, Kamm MA. *Inflamm Bowel Dis.* 2011 Sep;17(9):1987-99.
40. Massive tracheal-esophageal fistula secondary to lymphoma treated with an esophageal stent. Allen PB, Kettle PJ, Mainie I. *Clin Gastroenterol Hepatol.* 2011 Jun;9(6):e52-3.
41. Dysplastic lesions in ulcerative colitis: changing paradigms. Allen PB, Kamm MA, De Cruz P, Desmond PV. *Inflamm Bowel Dis.* 2010 Nov;16(11):1978-83.
42. How do patients with inflammatory bowel disease want their biological therapy administered? Allen PB, Lindsay H, Tham TC. *BMC Gastroenterol.* 2010 Jan 10;10:1.
43. An Interesting Case of Recurrent Small Bowel Obstruction. Allen PB, De Cruz P, Efthymiou M, Fox A, Taylor AC, Desmond PV. *Case Rep Gastroenterol.* 2009 Nov 21;3(3):408-413.
44. Central and peripheral haemodynamic effects of L-NAME infusion in healthy volunteers. Morgan DR, Silke B, Dixon LJ, Allen PB, Hanratty CG, McVeigh GE. *Eur J Clin Pharmacol.* 2003 Jul;59(3):195-9.
45. Early vascular abnormalities and de novo nitrate tolerance in diabetes mellitus. McVeigh GE, Morgan DR, Allen P, Trimble M, Hamilton P, Dixon LJ, Silke B, Hayes JR. *Diabetes Obes Metab.* 2002.
46. Effect of nitric oxide modulation on systemic haemodynamics and platelet activation determined by P-selectin expression. Ritchie JL, Alexander HD, Allen P, Morgan D, McVeigh GE. *Br J Haematol.* 2002 Mar;116(4):892-8.
47. Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis. McVeigh GE, Allen PB, Morgan DR, Hanratty CG, Silke B. *Clin Sci (Lond).* 2001 Apr;100(4):387-93.
48. Nitric Oxide and its effects on blood vessel tone Allen PB, McVeigh GE.. Published in *Journal of Human Hypertension* (2001).

Book Chapters

1. Allen PB, Whelan G, Talley N. Food allergies and intolerance. Book Chapter 18.(p238-46) Clinical Gastroenterology 3rd edition. Elsevier. Jan 2012.
2. Allen PB, Tham TCK. Book chapter entitled: 'Approach to Upper GI Bleeding', published in textbook entitled 'Gastrointestinal Emergencies' 2e John Wiley Publishing (London)